The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Hanover Media Strategy Limited naming Colm Burke .

Filed returns
55
match these filters
Matching filed returns per period 0 1 2 3 5 Jan–Apr 2017: 1 filed returns May–Aug 2017: 3 filed returns Sep–Dec 2017: 4 filed returns Jan–Apr 2018: 2 filed returns May–Aug 2018: 1 filed returns Sep–Dec 2018: 1 filed returns Jan–Apr 2019: 2 filed returns May–Aug 2019: 2 filed returns Sep–Dec 2019: 1 filed returns Jan–Apr 2020: 4 filed returns May–Aug 2020: 3 filed returns Sep–Dec 2020: 3 filed returns Jan–Apr 2021: 3 filed returns May–Aug 2021: 1 filed returns Sep–Dec 2021: 1 filed returns Jan–Apr 2022: 1 filed returns Sep–Dec 2022: 2 filed returns Jan–Apr 2023: 1 filed returns May–Aug 2023: 1 filed returns Sep–Dec 2023: 4 filed returns Jan–Apr 2024: 1 filed returns Sep–Dec 2024: 3 filed returns Jan–Apr 2025: 1 filed returns May–Aug 2025: 2 filed returns Sep–Dec 2025: 4 filed returns Jan–Apr 2026: 2 filed returns May–Aug 2026: 1 filed returns 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
May–Aug 2026 Hanover Media Strategy Limited Health Discussion of proposed Early Access Programme of innovative oncology medicines (Public policy or programme) 3 On lobbying.ie
Jan–Apr 2026 Hanover Media Strategy Limited Health Discussion of proposed Early Access Programme for innovative oncology medicines. (Public policy or programme) 3 On lobbying.ie
Jan–Apr 2026 Hanover Media Strategy Limited Health Briefing on the school flu vaccine rollout in the context of a forthcoming Joint Committee on Health hearing on vaccine policy (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2025 Hanover Media Strategy Limited Health Letter to Joint Committee on Health concerning the current inequities in access to innovative oncology medicines in Ireland. (Public policy or programme) 3 On lobbying.ie
Sep–Dec 2025 Hanover Media Strategy Limited Health AV Room Briefing Event to discuss a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) 41 On lobbying.ie
Sep–Dec 2025 Hanover Media Strategy Limited Children and Youth Affairs Meeting request to discuss Tigers Childcare's Pre Budget 2026 Submission (Public policy or programme) 44 On lobbying.ie
Sep–Dec 2025 Hanover Media Strategy Limited Health Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) 33 On lobbying.ie
May–Aug 2025 Hanover Media Strategy Limited Children and Youth Affairs AV Room Briefing Event to discuss the ongoing crises facing the early years and childcare sector (Public policy or programme) 29 On lobbying.ie
May–Aug 2025 Hanover Media Strategy Limited Health Meeting request to discuss protection for over 65s in winter flu season (Public policy or programme) 19 On lobbying.ie
Jan–Apr 2025 Hanover Media Strategy Limited Health Rare Disease & Life Sciences Policy (Public policy or programme) 3 On lobbying.ie
Sep–Dec 2024 Hanover Media Strategy Limited Health AstraZeneca health policy priorities for the new Programme for Government (Public policy or programme) 8 On lobbying.ie
Sep–Dec 2024 Hanover Media Strategy Limited Health Life Sciences Strategy for Ireland (Public policy or programme) 10 On lobbying.ie
Sep–Dec 2024 Hanover Media Strategy Limited Health To share information on the level of vaccine protection for the over 65s population in Ireland (Public policy or programme) 5 On lobbying.ie
Jan–Apr 2024 Hanover Media Strategy Limited Health Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) 15 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Health Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) 3 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Health Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) 15 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Transport Correspondence regarding the Taxi Supply Shortage (Public policy or programme) 44 On lobbying.ie
Sep–Dec 2023 Hanover Media Strategy Limited Health Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) 3 On lobbying.ie
May–Aug 2023 Hanover Media Strategy Limited Health Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) 23 On lobbying.ie
Jan–Apr 2023 Hanover Media Strategy Limited Health The landscape for innovative and precision medicines in Ireland. (Public policy or programme) 12 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Health Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) 18 On lobbying.ie
Sep–Dec 2022 Hanover Media Strategy Limited Health Rare Disease Policy (Legislation) 9 On lobbying.ie
Jan–Apr 2022 Hanover Media Strategy Limited Health Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) 14 On lobbying.ie
Sep–Dec 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
May–Aug 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 9 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2021 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 9 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 14 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Provided update to select politicians on developments in Oncology therapies and barriers to access (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2020 Hanover Media Strategy Limited Health Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) 22 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
May–Aug 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 16 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) 5 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) 10 On lobbying.ie
Jan–Apr 2020 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 8 On lobbying.ie
Sep–Dec 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 7 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 4 On lobbying.ie
May–Aug 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) 15 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health Creation of national policy with regard to Orphan Medicinal Products (Legislation) 5 On lobbying.ie
Jan–Apr 2019 Hanover Media Strategy Limited Health The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 10 On lobbying.ie
May–Aug 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 13 On lobbying.ie
Jan–Apr 2018 Hanover Media Strategy Limited Health Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) 12 On lobbying.ie
Jan–Apr 2018 Hanover Media Strategy Limited Health Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) 12 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) 16 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Telehealth policy in Ireland (Public policy or programme) 5 On lobbying.ie
Sep–Dec 2017 Hanover Media Strategy Limited Health Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) 16 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 52 94.5%
Children and Youth Affairs 2 3.6%
Transport 1 1.8%